Revision of PRECAUTIONS

Alacepril, Imidapril hydrochloride, Enalapril maleate, Captopril, Quinapril hydrochloride, Cilazapril hydrate, Temocapril hydrochloride, Delapril hydrochloride, Trandolapril, Benazepril hydrochloride, Perindopril erbumine, and Lisinopril hydrate

June 3, 2014

Non-proprietary Name
- Alacepril
- Imidapril hydrochloride
- Enalapril maleate
- Captopril
- Quinapril hydrochloride
- Cilazapril hydrate
- Temocapril hydrochloride
- Delapril hydrochloride
- Trandolapril
- Benazepril hydrochloride
- Perindopril erbumine
- Lisinopril hydrate

Safety measure
Precautions section should be revised in the package inserts.

In Precautions for concomitant use subsection of Interactions section, the following texts should be added (underlined parts are revised):

Angiotensin II receptor blockers (ARBs)

Clinical symptoms and measures:
Renal impairment, hyperkalaemia, and/or hypotension may occur. Patients should be carefully monitored for renal function, serum potassium level, and blood pressure.

Mechanism and risk factors:
Concomitant use with ARBs may increase an effect of renin-angiotensin system blockade.